Illinois General Assembly - Full Text of HB4707
Illinois General Assembly

Previous General Assemblies

Full Text of HB4707  100th General Assembly

HB4707 100TH GENERAL ASSEMBLY

  
  

 


 
100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018
HB4707

 

Introduced , by Rep. Sue Scherer

 

SYNOPSIS AS INTRODUCED:
 
225 ILCS 80/15.1
720 ILCS 570/204  from Ch. 56 1/2, par. 1204
720 ILCS 570/206  from Ch. 56 1/2, par. 1206

    Amends the Illinois Controlled Substances Act. Changes the classification of Hydrocodone from a Schedule II controlled substance to a Schedule I controlled substance. Amends the Illinois Optometric Practice Act of 1987 to make a conforming change.


LRB100 16559 RLC 31691 b

CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY

 

 

A BILL FOR

 

HB4707LRB100 16559 RLC 31691 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Optometric Practice Act of 1987 is
5amended by changing Section 15.1 as follows:
 
6    (225 ILCS 80/15.1)
7    (Section scheduled to be repealed on January 1, 2027)
8    Sec. 15.1. Diagnostic and therapeutic authority.
9    (a) For purposes of the Act, "ocular pharmaceutical agents"
10means topical anesthetics, topical mydriatics, topical
11cycloplegics, topical miotics and mydriatic reversing agents,
12anti-infective agents, anti-allergy agents, anti-glaucoma
13agents (except oral carbonic anhydrase inhibitors, which may be
14prescribed only in a quantity sufficient to provide treatment
15for up to 30 days), anti-inflammatory agents (except oral
16steroids, which may be prescribed only in a quantity sufficient
17to provide treatment for up to 7 days), over-the-counter
18agents, analgesic agents, anti-dry eye agents, and agents for
19the treatment of hypotrichosis.
20    (a-3) In addition to ocular pharmaceutical agents that fall
21within the categories set forth in subsection (a) of this
22Section, the Board may add a pharmaceutical agent approved by
23the FDA or class of agents for the purpose of the diagnosis or

 

 

HB4707- 2 -LRB100 16559 RLC 31691 b

1treatment of conditions of the eye and adnexa after
2consideration of the agent's systemic effects, side effects,
3and the use of the agent within the practice of optometry. The
4Board shall consider requests for additional agents and make
5recommendations within 90 days after the receipt of the
6request.
7    Within 45 days after the Board's recommendation to the
8Department of a pharmaceutical agent or class of agents, the
9Department shall promulgate rules necessary to allow for the
10prescribing or administering of the pharmaceutical agent or
11class of agents under this Act.
12    (a-5) Ocular pharmaceutical agents administered by
13injection may be used only for the treatment of anaphylaxis.
14    (a-10) Oral pharmaceutical agents may be prescribed for a
15child under 5 years of age only in consultation with a
16physician licensed to practice medicine in all its branches.
17    (a-15) The authority to prescribe a Schedule III, IV, or V
18controlled substance shall include analgesic agents only in a
19quantity sufficient to provide treatment for up to 72 hours.
20The prescription of a Schedule II controlled substance is
21prohibited, except for Dihydrocodeinone (Hydrocodone) with one
22or more active, non-narcotic ingredients only in a quantity
23sufficient to provide treatment for up to 72 hours, and only if
24such formulations of Dihydrocodeinone are reclassified as
25Schedule II by federal regulation.
26    (b) A licensed optometrist may remove superficial foreign

 

 

HB4707- 3 -LRB100 16559 RLC 31691 b

1bodies from the human eye and adnexa and may give orders for
2patient care to a nurse or other health care provider licensed
3to practice under Illinois law.
4    (c) An optometrist's license shall be revoked or suspended
5by the Department upon recommendation of the Board based upon
6either of the following causes:
7        (1) grave or repeated misuse of any ocular
8    pharmaceutical agent; and
9        (2) the use of any agent or procedure in the course of
10    optometric practice by an optometrist not properly
11    authorized under this Act.
12    (d) The Secretary of Financial and Professional Regulation
13shall notify the Director of Public Health as to the categories
14of ocular pharmaceutical agents permitted for use by an
15optometrist. The Director of Public Health shall in turn notify
16every licensed pharmacist in the State of the categories of
17ocular pharmaceutical agents that can be utilized and
18prescribed by an optometrist.
19(Source: P.A. 98-1111, eff. 8-26-14; 99-909, eff. 1-1-17.)
 
20    Section 10. The Illinois Controlled Substances Act is
21amended by changing Sections 204 and 206 as follows:
 
22    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
23    Sec. 204. (a) The controlled substances listed in this
24Section are included in Schedule I.

 

 

HB4707- 4 -LRB100 16559 RLC 31691 b

1    (b) Unless specifically excepted or unless listed in
2another schedule, any of the following opiates, including their
3isomers, esters, ethers, salts, and salts of isomers, esters,
4and ethers, whenever the existence of such isomers, esters,
5ethers and salts is possible within the specific chemical
6designation:
7        (1) Acetylmethadol;
8        (1.1) Acetyl-alpha-methylfentanyl
9    (N-[1-(1-methyl-2-phenethyl)-
10    4-piperidinyl]-N-phenylacetamide);
11        (2) Allylprodine;
12        (3) Alphacetylmethadol, except
13    levo-alphacetylmethadol (also known as levo-alpha-
14    acetylmethadol, levomethadyl acetate, or LAAM);
15        (4) Alphameprodine;
16        (5) Alphamethadol;
17        (6) Alpha-methylfentanyl
18    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
19    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
20    propanilido) piperidine;
21        (6.1) Alpha-methylthiofentanyl
22    (N-[1-methyl-2-(2-thienyl)ethyl-
23    4-piperidinyl]-N-phenylpropanamide);
24        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
25        (7.1) PEPAP
26    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);

 

 

HB4707- 5 -LRB100 16559 RLC 31691 b

1        (8) Benzethidine;
2        (9) Betacetylmethadol;
3        (9.1) Beta-hydroxyfentanyl
4    (N-[1-(2-hydroxy-2-phenethyl)-
5    4-piperidinyl]-N-phenylpropanamide);
6        (10) Betameprodine;
7        (11) Betamethadol;
8        (12) Betaprodine;
9        (13) Clonitazene;
10        (14) Dextromoramide;
11        (15) Diampromide;
12        (16) Diethylthiambutene;
13        (17) Difenoxin;
14        (18) Dimenoxadol;
15        (19) Dimepheptanol;
16        (20) Dimethylthiambutene;
17        (21) Dioxaphetylbutyrate;
18        (22) Dipipanone;
19        (23) Ethylmethylthiambutene;
20        (24) Etonitazene;
21        (25) Etoxeridine;
22        (26) Furethidine;
23        (26.1) Hydrocodone;
24        (27) Hydroxpethidine;
25        (28) Ketobemidone;
26        (29) Levomoramide;

 

 

HB4707- 6 -LRB100 16559 RLC 31691 b

1        (30) Levophenacylmorphan;
2        (31) 3-Methylfentanyl
3    (N-[3-methyl-1-(2-phenylethyl)-
4    4-piperidyl]-N-phenylpropanamide);
5        (31.1) 3-Methylthiofentanyl
6    (N-[(3-methyl-1-(2-thienyl)ethyl-
7    4-piperidinyl]-N-phenylpropanamide);
8        (32) Morpheridine;
9        (33) Noracymethadol;
10        (34) Norlevorphanol;
11        (35) Normethadone;
12        (36) Norpipanone;
13        (36.1) Para-fluorofentanyl
14    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
15    4-piperidinyl]propanamide);
16        (37) Phenadoxone;
17        (38) Phenampromide;
18        (39) Phenomorphan;
19        (40) Phenoperidine;
20        (41) Piritramide;
21        (42) Proheptazine;
22        (43) Properidine;
23        (44) Propiram;
24        (45) Racemoramide;
25        (45.1) Thiofentanyl
26    (N-phenyl-N-[1-(2-thienyl)ethyl-

 

 

HB4707- 7 -LRB100 16559 RLC 31691 b

1    4-piperidinyl]-propanamide);
2        (46) Tilidine;
3        (47) Trimeperidine;
4        (48) Beta-hydroxy-3-methylfentanyl (other name:
5    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
6    N-phenylpropanamide);
7        (49) Furanyl fentanyl (FU-F);
8        (50) Butyryl fentanyl;
9        (51) Valeryl fentanyl;
10        (52) Acetyl fentanyl;
11        (53) Beta-hydroxy-thiofentanyl;
12        (54) 3,4-dichloro-N-[2-
13    (dimethylamino)cyclohexyl]-N-
14    methylbenzamide (U-47700); 
15        (55) 4-chloro-N-[1-[2-
16    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
17    benzenesulfonamide (W-18); 
18        (56) 4-chloro-N-[1-(2-phenylethyl)
19    -2-piperidinylidene]-benzenesulfonamide (W-15); 
20        (57) acrylfentanyl (acryloylfentanyl). 
21    (c) Unless specifically excepted or unless listed in
22another schedule, any of the following opium derivatives, its
23salts, isomers and salts of isomers, whenever the existence of
24such salts, isomers and salts of isomers is possible within the
25specific chemical designation:
26        (1) Acetorphine;

 

 

HB4707- 8 -LRB100 16559 RLC 31691 b

1        (2) Acetyldihydrocodeine;
2        (3) Benzylmorphine;
3        (4) Codeine methylbromide;
4        (5) Codeine-N-Oxide;
5        (6) Cyprenorphine;
6        (7) Desomorphine;
7        (8) Diacetyldihydromorphine (Dihydroheroin);
8        (9) Dihydromorphine;
9        (10) Drotebanol;
10        (11) Etorphine (except hydrochloride salt);
11        (12) Heroin;
12        (13) Hydromorphinol;
13        (14) Methyldesorphine;
14        (15) Methyldihydromorphine;
15        (16) Morphine methylbromide;
16        (17) Morphine methylsulfonate;
17        (18) Morphine-N-Oxide;
18        (19) Myrophine;
19        (20) Nicocodeine;
20        (21) Nicomorphine;
21        (22) Normorphine;
22        (23) Pholcodine;
23        (24) Thebacon.
24    (d) Unless specifically excepted or unless listed in
25another schedule, any material, compound, mixture, or
26preparation which contains any quantity of the following

 

 

HB4707- 9 -LRB100 16559 RLC 31691 b

1hallucinogenic substances, or which contains any of its salts,
2isomers and salts of isomers, whenever the existence of such
3salts, isomers, and salts of isomers is possible within the
4specific chemical designation (for the purposes of this
5paragraph only, the term "isomer" includes the optical,
6position and geometric isomers):
7        (1) 3,4-methylenedioxyamphetamine
8    (alpha-methyl,3,4-methylenedioxyphenethylamine,
9    methylenedioxyamphetamine, MDA);
10        (1.1) Alpha-ethyltryptamine
11    (some trade or other names: etryptamine;
12    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
13    3-(2-aminobutyl)indole; a-ET; and AET);
14        (2) 3,4-methylenedioxymethamphetamine (MDMA);
15        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
16    (also known as: N-ethyl-alpha-methyl-
17    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
18    and MDEA);
19        (2.2) N-Benzylpiperazine (BZP);
20        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
21        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
22        (4) 3,4,5-trimethoxyamphetamine (TMA);
23        (5) (Blank);
24        (6) Diethyltryptamine (DET);
25        (7) Dimethyltryptamine (DMT);
26        (7.1) 5-Methoxy-diallyltryptamine;

 

 

HB4707- 10 -LRB100 16559 RLC 31691 b

1        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
2        (9) Ibogaine  (some trade and other names:
3    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
4    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
5    indole; Tabernanthe iboga);
6        (10) Lysergic acid diethylamide;
7        (10.1) Salvinorin A;
8        (10.5) Salvia divinorum (meaning all parts of the plant
9    presently classified botanically as Salvia divinorum,
10    whether growing or not, the seeds thereof, any extract from
11    any part of that plant, and every compound, manufacture,
12    salts, isomers, and salts of isomers whenever the existence
13    of such salts, isomers, and salts of isomers is possible
14    within the specific chemical designation, derivative,
15    mixture, or preparation of that plant, its seeds or
16    extracts);
17        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
18        (12) Peyote (meaning all parts of the plant presently
19    classified botanically as Lophophora williamsii Lemaire,
20    whether growing or not, the seeds thereof, any extract from
21    any part of that plant, and every compound, manufacture,
22    salts, derivative, mixture, or preparation of that plant,
23    its seeds or extracts);
24        (13) N-ethyl-3-piperidyl benzilate (JB 318);
25        (14) N-methyl-3-piperidyl benzilate;
26        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine

 

 

HB4707- 11 -LRB100 16559 RLC 31691 b

1    (also known as N-hydroxy-alpha-methyl-
2    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
3        (15) Parahexyl; some trade or other names:
4    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
5    dibenzo (b,d) pyran; Synhexyl;
6        (16) Psilocybin;
7        (17) Psilocyn;
8        (18) Alpha-methyltryptamine (AMT);
9        (19) 2,5-dimethoxyamphetamine
10    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
11        (20) 4-bromo-2,5-dimethoxyamphetamine
12    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
13    4-bromo-2,5-DMA);
14        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
15    Some trade or other names: 2-(4-bromo-
16    2,5-dimethoxyphenyl)-1-aminoethane;
17    alpha-desmethyl DOB, 2CB, Nexus;
18        (21) 4-methoxyamphetamine
19    (4-methoxy-alpha-methylphenethylamine;
20    paramethoxyamphetamine; PMA);
21        (22) (Blank);
22        (23) Ethylamine analog of phencyclidine.
23    Some trade or other names:
24    N-ethyl-1-phenylcyclohexylamine,
25    (1-phenylcyclohexyl) ethylamine,
26    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

 

 

HB4707- 12 -LRB100 16559 RLC 31691 b

1        (24) Pyrrolidine analog of phencyclidine. Some trade
2    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
3    PHP;
4        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
5        (26) 2,5-dimethoxy-4-ethylamphetamine
6    (another name: DOET);
7        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
8    (another name: TCPy);
9        (28) (Blank);
10        (29) Thiophene analog of phencyclidine (some trade
11    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
12    2-thienyl analog of phencyclidine; TPCP; TCP);
13        (29.1) Benzothiophene analog of phencyclidine. Some
14    trade or other names: BTCP or benocyclidine;
15        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
16        (30) Bufotenine (some trade or other names:
17    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
18    3-(2-dimethylaminoethyl)-5-indolol;
19    5-hydroxy-N,N-dimethyltryptamine;
20    N,N-dimethylserotonin; mappine);
21        (31) (Blank);  
22        (32) (Blank);  
23        (33) (Blank);  
24        (34) (Blank); 
25        (34.5) (Blank);  
26        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

 

 

HB4707- 13 -LRB100 16559 RLC 31691 b

1    (2-methyloctan-2-yl)-6a,7, 
2    10,10a-tetrahydrobenzo[c]chromen-1-ol
3    Some trade or other names: HU-210; 
4        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
5    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
6    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
7    salts, and salts of isomers; Some trade or other  
8    names: HU-210, Dexanabinol; 
9        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
10    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
11    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
12    Some trade or other names: HU-211;
13        (37) (Blank);
14        (38) (Blank);
15        (39) (Blank);
16        (40) (Blank);
17        (41) (Blank);
18        (42) Any compound structurally derived from
19    3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
20    by substitution at the nitrogen atom of the indole ring by
21    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
22    cycloalkylethyl, aryl halide, alkyl aryl halide,
23    1-(N-methyl-2-piperidinyl)methyl, or
24    2-(4-morpholinyl)ethyl whether or not further substituted
25    in the indole ring to any extent, whether or not
26    substituted in the naphthyl ring to any extent. Examples of

 

 

HB4707- 14 -LRB100 16559 RLC 31691 b

1    this structural class include, but are not limited to,
2    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
3        (43) Any compound structurally derived from
4    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
5    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
6    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7    halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    in the pyrrole ring to any extent, whether or not
10    substituted in the naphthyl ring to any extent. Examples of
11    this structural class include, but are not limited to,
12    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
13        (44) Any compound structurally derived from
14    1-(1-naphthylmethyl)indene by substitution at the
15    3-position of the indene ring by alkyl, haloalkyl, alkenyl,
16    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17    halide, 1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl whether or not further substituted
19    in the indene ring to any extent, whether or not
20    substituted in the naphthyl ring to any extent. Examples of
21    this structural class include, but are not limited to,
22    JWH-176;
23        (45) Any compound structurally derived from
24    3-phenylacetylindole by substitution at the nitrogen atom
25    of the indole ring with alkyl, haloalkyl, alkenyl,
26    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl

 

 

HB4707- 15 -LRB100 16559 RLC 31691 b

1    halide, 1-(N-methyl-2-piperidinyl)methyl, or
2    2-(4-morpholinyl)ethyl, whether or not further substituted
3    in the indole ring to any extent, whether or not
4    substituted in the phenyl ring to any extent. Examples of
5    this structural class include, but are not limited to,
6    JWH-167, JWH-250, JWH-251, and RCS-8;
7        (46) Any compound structurally derived from
8    2-(3-hydroxycyclohexyl)phenol by substitution at the
9    5-position of the phenolic ring by alkyl, haloalkyl,
10    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
11    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
12    2-(4-morpholinyl)ethyl, whether or not substituted in the
13    cyclohexyl ring to any extent. Examples of this structural
14    class include, but are not limited to, CP 47, 497 and its
15    C8 homologue (cannabicyclohexanol);
16        (46.1) Any compound structurally derived from
17    3-(benzoyl) indole with substitution at the nitrogen atom
18    of the indole ring by an alkyl, haloalkyl, alkenyl,
19    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20    halide, 1-(N-methyl-2-piperidinyl)methyl, or
21    2-(4-morpholinyl)ethyl group whether or not further
22    substituted in the indole ring to any extent and whether or
23    not substituted in the phenyl ring to any extent. Examples
24    of this structural class include, but are not limited to,
25    AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
26    RCS-4;

 

 

HB4707- 16 -LRB100 16559 RLC 31691 b

1        (47) (Blank);
2        (48) (Blank);
3        (49) (Blank);
4        (50) (Blank);
5        (51) (Blank);
6        (52) (Blank);
7        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
8    Some trade or other names: 2C-T-7;
9        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some trade
10    or other names: 2C-E;
11        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
12    trade or other names: 2C-D;
13        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
14    trade or other names: 2C-C;
15        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
16    or other names: 2C-I;
17        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
18    trade or other names: 2C-T-2;
19        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
20    Some trade or other names: 2C-T-4;
21        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
22    other names: 2C-H;
23        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some trade
24    or other names: 2C-N;
25        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
26    trade or other names: 2C-P;

 

 

HB4707- 17 -LRB100 16559 RLC 31691 b

1        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. Some
2    trade or other names: 2C-G;
3        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
4    phenethylamine referred to in subparagraphs (20.1), (53),
5    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
6    (53.8), (53.9), and (53.10) including, but not limited to,
7    25I-NBOMe and 25C-NBOMe;
8        (54) 5-Methoxy-N,N-diisopropyltryptamine;
9        (55) (Blank);
10        (56) (Blank);
11        (57) (Blank);
12        (58) (Blank);
13        (59) 3-cyclopropoylindole with substitution at the
14    nitrogen atom of the indole ring by alkyl, haloalkyl,
15    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
16    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indole ring to any extent, whether or not
19    substituted on the cyclopropyl ring to any extent:
20    including, but not limited to, XLR11, UR144, FUB-144;
21        (60) 3-adamantoylindole with substitution at the
22    nitrogen atom of the indole ring by alkyl, haloalkyl,
23    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
24    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
25    2-(4-morpholinyl)ethyl, whether or not further substituted
26    on the indole ring to any extent, whether or not

 

 

HB4707- 18 -LRB100 16559 RLC 31691 b

1    substituted on the adamantyl ring to any extent: including,
2    but not limited to, AB-001;
3        (61) N-(adamantyl)-indole-3-carboxamide with
4    substitution at the nitrogen atom of the indole ring by
5    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
6    cycloalkylethyl, aryl halide, alkyl aryl halide,
7    1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the indole ring to any extent, whether or not
10    substituted on the adamantyl ring to any extent: including,
11    but not limited to, APICA/2NE-1, STS-135;
12        (62) N-(adamantyl)-indazole-3-carboxamide with
13    substitution at a nitrogen atom of the indazole ring by
14    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15    cycloalkylethyl, aryl halide, alkyl aryl halide,
16    1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indazole ring to any extent, whether or not
19    substituted on the adamantyl ring to any extent: including,
20    but not limited to, AKB48, 5F-AKB48;
21        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
22    with substitution at the nitrogen atom of the indole ring
23    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
24    cycloalkylethyl, aryl halide, alkyl aryl halide,
25    1-(N-methyl-2-piperidinyl)methyl, or
26    2-(4-morpholinyl)ethyl, whether or not further substituted

 

 

HB4707- 19 -LRB100 16559 RLC 31691 b

1    on the indole ring to any extent, whether or not
2    substituted on the quinoline ring to any extent: including,
3    but not limited to, PB22, 5F-PB22, FUB-PB-22;
4        (64) 3-(1-naphthoyl)indazole with substitution at the
5    nitrogen atom of the indazole ring by alkyl, haloalkyl,
6    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the indazole ring to any extent, whether or not
10    substituted on the naphthyl ring to any extent: including,
11    but not limited to, THJ-018, THJ-2201;
12        (65) 2-(1-naphthoyl)benzimidazole with substitution at
13    the nitrogen atom of the benzimidazole ring by alkyl,
14    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15    aryl halide, alkyl aryl halide,
16    1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the benzimidazole ring to any extent, whether or not
19    substituted on the naphthyl ring to any extent: including,
20    but not limited to, FUBIMINA;
21        (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
22    3-carboxamide with substitution on the nitrogen atom of the
23    indazole ring by alkyl, haloalkyl, alkenyl,
24    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
25    halide, 1-(N-methyl-2-piperidinyl)methyl, or
26    2-(4-morpholinyl)ethyl, whether or not further substituted

 

 

HB4707- 20 -LRB100 16559 RLC 31691 b

1    on the indazole ring to any extent: including, but not
2    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
3        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
4    indazole-3-carboxamide with substitution on the nitrogen
5    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
6    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7    halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the indazole ring to any extent: including, but not
10    limited to, ADB-PINACA, ADB-FUBINACA;
11        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
12    indole-3-carboxamide with substitution on the nitrogen
13    atom of the indole ring by alkyl, haloalkyl, alkenyl,
14    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15    halide, 1-(N-methyl-2-piperidinyl)methyl, or
16    2-(4-morpholinyl)ethyl, whether or not further substituted
17    on the indole ring to any extent: including, but not
18    limited to, ADBICA, 5F-ADBICA;
19        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
20    3-carboxamide with substitution on the nitrogen atom of the
21    indole ring by alkyl, haloalkyl, alkenyl,
22    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23    halide, 1-(N-methyl-2-piperidinyl)methyl, or
24    2-(4-morpholinyl)ethyl, whether or not further substituted
25    on the indole ring to any extent: including, but not
26    limited to, ABICA, 5F-ABICA;

 

 

HB4707- 21 -LRB100 16559 RLC 31691 b

1        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
2    methylbutanoate with substitution on the nitrogen atom of
3    the indazole ring by alkyl, haloalkyl, alkenyl,
4    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5    halide, 1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the indazole ring to any extent: including, but not
8    limited to, AMB, 5F-AMB; .
9        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
10    dimethylbutanoate with substitution on the nitrogen atom
11    of the indazole ring by alkyl, haloalkyl, alkenyl,
12    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13    halide, 1-(N-methyl-2-piperidinyl)methyl, or
14    2-(4-morpholinyl)ethyl, whether or not further substituted
15    on the indazole ring to any extent: including, but not
16    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
17        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
18    methylbutanoate with substitution on the nitrogen atom of
19    the indole ring by alkyl, haloalkyl, alkenyl,
20    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
21    halide, 1-(N-methyl-2-piperidinyl)methyl, or
22    2-(4-morpholinyl)ethyl, whether or not further substituted
23    on the indazole ring to any extent: including, but not
24    limited to, MMB018, MMB2201, and AMB-CHMICA;
25        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
26    dimethylbutanoate with substitution on the nitrogen atom

 

 

HB4707- 22 -LRB100 16559 RLC 31691 b

1    of the indole ring by alkyl, haloalkyl, alkenyl,
2    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3    halide, 1-(N-methyl-2-piperidinyl)methyl, or
4    2-(4-morpholinyl)ethyl, whether or not further substituted
5    on the indazole ring to any extent: including, but not
6    limited to, MDMB-CHMICA;
7        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
8    indazole-3-carboxamide with substitution on the nitrogen
9    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11    halide, 1-(N-methyl-2-piperidinyl)methyl, or
12    2-(4-morpholinyl)ethyl, whether or not further substituted
13    on the indazole ring to any     extent: including, but not
14    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
15        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
16    3-carboxamide with substitution on the nitrogen atom of the
17    indole ring by alkyl, haloalkyl, alkenyl,
18    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
19    halide, 1-(N-methyl-2-piperidinyl)methyl, or
20    2-(4-morpholinyl)ethyl, whether or not further substituted
21    on the indazole ring to any extent: including, but not
22    limited to, APP-PICA and 5-fluoro-APP-PICA;
23        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
24    4-AcO-DMT;
25        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
26    name 5-MeO-MIPT;

 

 

HB4707- 23 -LRB100 16559 RLC 31691 b

1        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
2        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
3        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
4        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
5    (4-HO-MiPT);
6        (82) Fluorophenylpiperazine;
7        (83) Methoxetamine;
8        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
9    ethcathinone).
10    (e) Unless specifically excepted or unless listed in
11another schedule, any material, compound, mixture, or
12preparation which contains any quantity of the following
13substances having a depressant effect on the central nervous
14system, including its salts, isomers, and salts of isomers
15whenever the existence of such salts, isomers, and salts of
16isomers is possible within the specific chemical designation:
17        (1) mecloqualone;
18        (2) methaqualone; and
19        (3) gamma hydroxybutyric acid.
20    (f) Unless specifically excepted or unless listed in
21another schedule, any material, compound, mixture, or
22preparation which contains any quantity of the following
23substances having a stimulant effect on the central nervous
24system, including its salts, isomers, and salts of isomers:
25        (1) Fenethylline;
26        (2) N-ethylamphetamine;

 

 

HB4707- 24 -LRB100 16559 RLC 31691 b

1        (3) Aminorex (some other names:
2    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
3    4-5-dihydro-5-phenyl-2-oxazolamine) and its
4    salts, optical isomers, and salts of optical isomers;
5        (4) Methcathinone (some other names:
6    2-methylamino-1-phenylpropan-1-one;
7    Ephedrone; 2-(methylamino)-propiophenone;
8    alpha-(methylamino)propiophenone; N-methylcathinone;
9    methycathinone; Monomethylpropion; UR 1431) and its
10    salts, optical isomers, and salts of optical isomers;
11        (5) Cathinone (some trade or other names:
12    2-aminopropiophenone; alpha-aminopropiophenone;
13    2-amino-1-phenyl-propanone; norephedrone);
14        (6) N,N-dimethylamphetamine (also known as:
15    N,N-alpha-trimethyl-benzeneethanamine;
16    N,N-alpha-trimethylphenethylamine);
17        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
18    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
19        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
20        (9) Halogenated amphetamines and
21    methamphetamines - any compound derived from either
22    amphetamine or methamphetamine through the substitution
23    of a halogen on the phenyl ring, including, but not
24    limited to, 2-fluoroamphetamine, 3-
25    fluoroamphetamine and 4-fluoroamphetamine; 
26        (10) Aminopropylbenzofuran (APB):

 

 

HB4707- 25 -LRB100 16559 RLC 31691 b

1    including 4-(2-Aminopropyl) benzofuran, 5-
2    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
3    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
4        (11) Aminopropyldihydrobenzofuran (APDB):
5    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
6    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
7    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
8    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
9        (12) Methylaminopropylbenzofuran
10    (MAPB): including 4-(2-methylaminopropyl)
11    benzofuran, 5-(2-methylaminopropyl)benzofuran,
12    6-(2-methylaminopropyl)benzofuran
13    and 7-(2-methylaminopropyl)benzofuran. 
14    (g) Temporary listing of substances subject to emergency
15scheduling. Any material, compound, mixture, or preparation
16that contains any quantity of the following substances:
17        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
18    (benzylfentanyl), its optical isomers, isomers, salts, and
19    salts of isomers;
20        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
21    phenylpropanamide (thenylfentanyl), its optical isomers,
22    salts, and salts of isomers.
23    (h) Synthetic cathinones. Unless specifically excepted,
24any chemical compound which is not approved by the United
25States Food and Drug Administration or, if approved, is not
26dispensed or possessed in accordance with State or federal law,

 

 

HB4707- 26 -LRB100 16559 RLC 31691 b

1not including bupropion, structurally derived from
22-aminopropan-1-one by substitution at the 1-position with
3either phenyl, naphthyl, or thiophene ring systems, whether or
4not the compound is further modified in one or more of the
5following ways:
6        (1) by substitution in the ring system to any extent
7    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
8    halide substituents, whether or not further substituted in
9    the ring system by one or more other univalent
10    substituents. Examples of this class include, but are not
11    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
12        (2) by substitution at the 3-position with an acyclic
13    alkyl substituent. Examples of this class include, but are
14    not limited to, 2-methylamino-1-phenylbutan-1-one
15    (buphedrone); or
16        (3) by substitution at the 2-amino nitrogen atom with
17    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
18    inclusion of the 2-amino nitrogen atom in a cyclic
19    structure. Examples of this class include, but are not
20    limited to, Dimethylcathinone, Ethcathinone, and
21    a-Pyrrolidinopropiophenone (a-PPP).
22(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
23100-368, eff. 1-1-18; revised 10-5-17.)
 
24    (720 ILCS 570/206)  (from Ch. 56 1/2, par. 1206)
25    Sec. 206. (a) The controlled substances listed in this

 

 

HB4707- 27 -LRB100 16559 RLC 31691 b

1Section are included in Schedule II.
2    (b) Unless specifically excepted or unless listed in
3another schedule, any of the following substances whether
4produced directly or indirectly by extraction from substances
5of vegetable origin, or independently by means of chemical
6synthesis, or by combination of extraction and chemical
7synthesis:
8        (1) Opium and opiates, and any salt, compound,
9    derivative or preparation of opium or opiate, excluding
10    apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
11    nalmefene, naloxone, and naltrexone, and their respective
12    salts, but including the following:
13            (i) Raw Opium;
14            (ii) Opium extracts;
15            (iii) Opium fluid extracts;
16            (iv) Powdered opium;
17            (v) Granulated opium;
18            (vi) Tincture of opium;
19            (vii) Codeine;
20            (viii) Ethylmorphine;
21            (ix) Etorphine Hydrochloride;
22            (x) (Blank); Hydrocodone;
23            (xi) Hydromorphone;
24            (xii) Metopon;
25            (xiii) Morphine;
26            (xiii.5) 6-Monoacetylmorphine;

 

 

HB4707- 28 -LRB100 16559 RLC 31691 b

1            (xiv) Oxycodone;
2            (xv) Oxymorphone;
3            (xv.5) Tapentadol;
4            (xvi) Thebaine;
5            (xvii) Thebaine-derived butorphanol.
6            (xviii) Methorphan, except drug products
7        containing dextromethorphan that may be dispensed
8        pursuant to a prescription order of a practitioner and
9        are sold in compliance with the safety and labeling
10        standards as set forth by the United States Food and
11        Drug Administration, or drug products containing
12        dextromethorphan that are sold in solid, tablet,
13        liquid, capsule, powder, thin film, or gel form and
14        which are formulated, packaged, and sold in dosages and
15        concentrations for use as an over-the-counter drug
16        product. For the purposes of this Section,
17        "over-the-counter drug product" means a drug that is
18        available to consumers without a prescription and sold
19        in compliance with the safety and labeling standards as
20        set forth by the United States Food and Drug
21        Administration.
22        (2) Any salt, compound, isomer, derivative or
23    preparation thereof which is chemically equivalent or
24    identical with any of the substances referred to in
25    subparagraph (1), but not including the isoquinoline
26    alkaloids of opium;

 

 

HB4707- 29 -LRB100 16559 RLC 31691 b

1        (3) Opium poppy and poppy straw;
2        (4) Coca leaves and any salt, compound, isomer, salt of
3    an isomer, derivative, or preparation of coca leaves
4    including cocaine or ecgonine, and any salt, compound,
5    isomer, derivative, or preparation thereof which is
6    chemically equivalent or identical with any of these
7    substances, but not including decocainized coca leaves or
8    extractions of coca leaves which do not contain cocaine or
9    ecgonine (for the purpose of this paragraph, the term
10    "isomer" includes optical, positional and geometric
11    isomers);
12        (5) Concentrate of poppy straw (the crude extract of
13    poppy straw in either liquid, solid or powder form which
14    contains the phenanthrine alkaloids of the opium poppy).
15    (c) Unless specifically excepted or unless listed in
16another schedule any of the following opiates, including their
17isomers, esters, ethers, salts, and salts of isomers, whenever
18the existence of these isomers, esters, ethers and salts is
19possible within the specific chemical designation, dextrorphan
20excepted:
21        (1) Alfentanil;
22        (1.1) Carfentanil;
23        (1.2) Thiafentanyl;
24        (2) Alphaprodine;
25        (3) Anileridine;
26        (4) Bezitramide;

 

 

HB4707- 30 -LRB100 16559 RLC 31691 b

1        (5) Bulk Dextropropoxyphene (non-dosage forms);
2        (6) Dihydrocodeine;
3        (7) Diphenoxylate;
4        (8) Fentanyl;
5        (9) Sufentanil;
6        (9.5) Remifentanil;
7        (10) Isomethadone;
8        (11) (Blank);
9        (12) Levorphanol (Levorphan);
10        (13) Metazocine;
11        (14) Methadone;
12        (15) Methadone-Intermediate,
13    4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
14        (16) Moramide-Intermediate,
15    2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
16    acid;
17        (17) Pethidine (meperidine);
18        (18) Pethidine-Intermediate-A,
19    4-cyano-1-methyl-4-phenylpiperidine;
20        (19) Pethidine-Intermediate-B,
21    ethyl-4-phenylpiperidine-4-carboxylate;
22        (20) Pethidine-Intermediate-C,
23    1-methyl-4-phenylpiperidine-4-carboxylic acid;
24        (21) Phenazocine;
25        (22) Piminodine;
26        (23) Racemethorphan;

 

 

HB4707- 31 -LRB100 16559 RLC 31691 b

1        (24) (Blank);
2        (25) Levo-alphacetylmethadol (some other names:
3    levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
4    (d) Unless specifically excepted or unless listed in
5another schedule, any material, compound, mixture, or
6preparation which contains any quantity of the following
7substances having a stimulant effect on the central nervous
8system:
9        (1) Amphetamine, its salts, optical isomers, and salts
10    of its optical isomers;
11        (2) Methamphetamine, its salts, isomers, and salts of
12    its isomers;
13        (3) Phenmetrazine and its salts;
14        (4) Methylphenidate;
15        (5) Lisdexamfetamine.
16    (e) Unless specifically excepted or unless listed in
17another schedule, any material, compound, mixture, or
18preparation which contains any quantity of the following
19substances having a depressant effect on the central nervous
20system, including its salts, isomers, and salts of isomers
21whenever the existence of such salts, isomers, and salts of
22isomers is possible within the specific chemical designation:
23        (1) Amobarbital;
24        (2) Secobarbital;
25        (3) Pentobarbital;
26        (4) Pentazocine;

 

 

HB4707- 32 -LRB100 16559 RLC 31691 b

1        (5) Phencyclidine;
2        (6) Gluthethimide;
3        (7) (Blank).
4    (f) Unless specifically excepted or unless listed in
5another schedule, any material, compound, mixture, or
6preparation which contains any quantity of the following
7substances:
8        (1) Immediate precursor to amphetamine and
9    methamphetamine:
10            (i) Phenylacetone
11        Some trade or other names: phenyl-2-propanone;
12        P2P; benzyl methyl ketone; methyl benzyl ketone.
13        (2) Immediate precursors to phencyclidine:
14            (i) 1-phenylcyclohexylamine;
15            (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
16        (3) Nabilone.
17(Source: P.A. 100-368, eff. 1-1-18.)